Thomas R. Fleming

43.0k total citations · 12 hit papers
223 papers, 21.1k citations indexed

About

Thomas R. Fleming is a scholar working on Statistics and Probability, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas R. Fleming has authored 223 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Statistics and Probability, 43 papers in Oncology and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas R. Fleming's work include Statistical Methods in Clinical Trials (60 papers), Health Systems, Economic Evaluations, Quality of Life (31 papers) and Statistical Methods and Inference (24 papers). Thomas R. Fleming is often cited by papers focused on Statistical Methods in Clinical Trials (60 papers), Health Systems, Economic Evaluations, Quality of Life (31 papers) and Statistical Methods and Inference (24 papers). Thomas R. Fleming collaborates with scholars based in United States, United Kingdom and Switzerland. Thomas R. Fleming's co-authors include David P. Harrington, Peter C. O’Brien, Dorota M. Dabrowska, Margaret S. Pepe, Patricia M. Grambsch, D. Y. Lin, John H. Powers, Lloyd D. Fisher, Victor De Gruttola and Scott S. Emerson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Thomas R. Fleming

219 papers receiving 20.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Multiple Testing Procedure for Clinical Trials

1979 2.2k citations Thomas R. Fleming et al. profile →
Counting Processes and Survival Analysis.

1992 1.6k citations Thomas R. Fleming, David P. Harrington et al. profile →
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1999 1.2k citations Thomas R. Fleming, Lynda Emel et al. profile →
Surrogate End Points in Clinical Trials: Are We Being Misled?

1996 1.1k citations Thomas R. Fleming et al. Annals of Internal Medicine profile →
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure

2004 955 citations Thomas R. Fleming et al. profile →
A class of rank test procedures for censored survival data

1982 839 citations David P. Harrington, Thomas R. Fleming profile →
One-Sample Multiple Testing Procedure for Phase II Clinical Trials

1982 828 citations Thomas R. Fleming profile →
Prognosis in primary biliary cirrhosis: Model for decision making

1989 622 citations Patricia M. Grambsch, Thomas R. Fleming et al. profile →
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

1989 526 citations Thomas R. Fleming et al. profile →
Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis

1989 479 citations Patricia M. Grambsch, E. Rolland Dickson et al. profile →
High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy

1985 449 citations Thomas R. Fleming et al. profile →
Pediatric Pulmonary Hypertension

2013 323 citations Robyn J. Barst, Thomas R. Fleming et al. Journal of the American College of Cardiology profile →

Peers

Countries citing papers authored by Thomas R. Fleming

Since Specialization

Citations

This map shows the geographic impact of Thomas R. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas R. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas R. Fleming more than expected).

Fields of papers citing papers by Thomas R. Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas R. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas R. Fleming. The network helps show where Thomas R. Fleming may publish in the future.

Co-authorship network of co-authors of Thomas R. Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas R. Fleming. A scholar is included among the top collaborators of Thomas R. Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas R. Fleming. Thomas R. Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Methods for the estimation of direct and indirect vaccination effects by combining data from individual‐ and cluster‐randomized trials 2024 ·Statistics in Medicine ·Rui Wang, (unknown), Yunda Huang, (unknown), Natalie E. Dean, Susan S. Ellenberg, Thomas R. Fleming, Wenbin Lu, Ira M. Longini	1
2	The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis 2024 ·Biomedicines ·Bruce D. Forrest, Namita Goyal, Thomas R. Fleming, Paige M. Bracci, Neil R. Brett, (unknown), (unknown), (unknown), Michael S. McGrath	1
3	Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting 2023 ·JCO Global Oncology ·Brooke E. Wilson, Richard Sullivan, Richard Peto, (unknown), Christopher M. Booth, Gustavo Werutsky, Cary Adams, Agnès Saint-Raymond, Thomas R. Fleming, H. Kim Lyerly, Julie R. Gralow	6
4	Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines 2022 ·The Journal of Infectious Diseases ·Dan-Yu Lin, Donglin Zeng, Yu Gu, Philip R. Krause, Thomas R. Fleming	3
5	Achieving effective informed oversight by DMCs in COVID clinical trials 2020 ·Journal of Clinical Epidemiology ·David L. DeMets, Thomas R. Fleming	10
6	Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions 2019 ·PubMed ·Thomas R. Fleming, Victor DeGruttola, Deborah Donnell	1
7	Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and Accountability 2016 ·Science and Engineering Ethics ·David L. DeMets, Thomas R. Fleming, Gail Geller, David F. Ransohoff	7
8	New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension 2013 ·Journal of the American College of Cardiology ·Mardi Gomberg‐Maitland, Todd M. Bull, Rajeev Saggar, Robyn J. Barst, (unknown), Thomas R. Fleming, Friedrich Grimminger, Maurizio Rainisio, Duncan J. Stewart, Norman Stockbridge, Carlo Ventura, Hossein Ardeschir Ghofrani, Lewis J. Rubin	98
9	Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials 2012 ·American Journal of Respiratory and Critical Care Medicine ·Ganesh Raghu, Harold R. Collard, Kevin J. Anstrom, Kevin R. Flaherty, Thomas R. Fleming, Talmadge E. King, Fernando J. Martínez, Kevin K. Brown	154
10	Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial (Annals of Internal Medicine (2008) 149, (521-530)) 2009 ·Annals of Internal Medicine ·G. Simonneau, Leona J. Rubin, Nazzareno Galiè, Robyn J. Barst, Thomas R. Fleming, Adaani Frost	106
11	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension 2009 ·Journal of the American College of Cardiology ·Vallerie V. McLaughlin, David B. Badesch, Marion Delcroix, Thomas R. Fleming, Seán Gaine, Nazzareno Galiè, J. Simon R. Gibbs, Nick H. Kim, Ronald J. Oudiz, Andrew J. Peacock, Steeve Provencher, Olivier Sitbon, Victor F. Tapson, Werner Seeger	172
12	The independent statistician for data monitoring committees 2004 ·Statistics in Medicine ·David L. DeMets, Thomas R. Fleming	17
13	Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Avinash K. Shetty, Hoosen Coovadia, (unknown), Yvonne Maldonado, Lynne Mofenson, Susan H. Eshleman, Thomas R. Fleming, Lynda Emel, (unknown), David Katzenstein, (unknown), Charles C. Maponga, Anthony Mwatha, (unknown), Salim S. Abdool Karim, Mary T. Bassett	46
14	Insights from monitoring the CPCRA didanosine/zalcitabine trial 1995 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Thomas R. Fleming, (unknown), Anne I. Goldman, David L. DeMets, Cynthia A. Launer, Joyce A. Korvick, (unknown)	11
15	Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma 1993 ·Investigational New Drugs ·W. Henwood Harvey, Thomas R. Fleming, Phyllis J. Goodman, (unknown), Saul E. Rivkin, John S. Macdonald	4
16	Phase II Trial of Merbarone in Pancreatic Carcinoma 1993 ·American Journal of Clinical Oncology ·Eric H. Kraut, Thomas R. Fleming, John S. Macdonald, C. Harris Spiridonidis, James E. Bradof, Laurence H. Baker	8
17	Primary sclerosing cholangitis: Refinement and validation of survival models 1992 ·Gastroenterology ·E. Rolland Dickson, Paul A. Murtaugh, Russell H. Wiesner, Patricia M. Grambsch, Thomas R. Fleming, Jürgen Ludwig, Nicholas F. LaRusso, Michael Malinchoc, Roger W. Chapman, Marshall M. Kaplan, Willis C. Maddrey, Roger Williams, Mark Farrant, Alice Langworthy	211
18	Evaluation of active control trials in AIDS. 1990 ·PubMed ·Thomas R. Fleming	49
19	A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. 1990 ·PubMed ·Robert P. Whitehead, Thomas R. Fleming, John S. Macdonald, Phyllis J. Goodman, John R. Neefe, Thomas J. Braun, Lode J. Swinnen, Evan M. Hersh	21
20	A class of hypothesis tests for one and two sample censored survival data 1981 ·Communication in Statistics- Theory and Methods ·Thomas R. Fleming, David P. Harrington	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact